Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.

Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP.

J Crohns Colitis. 2017 Mar 4. doi: 10.1093/ecco-jcc/jjx032. [Epub ahead of print]

PMID:
28333362
2.

Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Dotan I, Levy-Nissenbaum E, Chowers Y, Fich A, Israeli E, Adar T, Shteingart S, Soreq H, Goldin E.

Dig Dis Sci. 2016 Nov;61(11):3246-3254.

PMID:
27572942
3.

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK.

Cochrane Database Syst Rev. 2016 May 18;(5):CD000478. doi: 10.1002/14651858.CD000478.pub4. Review.

PMID:
27192092
4.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543. doi: 10.1002/14651858.CD000543.pub4. Review.

5.

Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.

Zakko SF, Gordon GL, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR.

Postgrad Med. 2016;128(3):273-81. doi: 10.1080/00325481.2016.1152876.

PMID:
26861051
6.

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.

Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T; AJM300 Study Group..

Gastroenterology. 2015 Dec;149(7):1775-1783.e2. doi: 10.1053/j.gastro.2015.08.044.

7.

Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.

Magalhães-Costa P, Matos L, Chagas C.

BMJ Case Rep. 2015 May 2;2015. pii: bcr2014207928. doi: 10.1136/bcr-2014-207928.

PMID:
25935912
8.

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.

Böhm SK, Kruis W.

Clin Exp Gastroenterol. 2014 Sep 23;7:369-83. doi: 10.2147/CEG.S35691. Review.

9.

Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.

Rubin DT, Mody R, Davis KL, Wang CC.

Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727.

10.

Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.

Coman RM, Glover SC, Gjymishka A.

Expert Rev Clin Immunol. 2014 May;10(5):667-75. doi: 10.1586/1744666X.2014.902313. Review.

PMID:
24689504
11.

Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004118. doi: 10.1002/14651858.CD004118.pub2. Review.

PMID:
23152224
12.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD000543.

PMID:
23076889
13.

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000478. doi: 10.1002/14651858.CD000478.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD000478.

PMID:
22972046
14.

Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.

Heyman MB, Kierkus J, Spénard J, Shbaklo H, Giguere M.

Inflamm Bowel Dis. 2010 Nov;16(11):1931-9. doi: 10.1002/ibd.21256.

15.

Mesalazine-induced multi-organ hypersensitivity.

Sposato B, Allegri MP, Riccardi MP, Chigiotti S, Nencioni C, Ricciardi B, Carli T, Cresti A, Perari MG, Migliorini MG, Toti M.

Clin Drug Investig. 2010;30(6):413-7. doi: 10.2165/11535480-000000000-00000.

PMID:
20441247
16.
17.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Sutherland L, Macdonald JK.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000544. Review. Update in: Cochrane Database Syst Rev. 2012;10:CD000544.

PMID:
16625537
18.

Transdermal nicotine for induction of remission in ulcerative colitis.

McGrath J, McDonald JW, Macdonald JK.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004722. Review.

PMID:
15495126
19.

Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease.

Wong JM, Wei SC.

J Formos Med Assoc. 2003 Sep;102(9):613-9.

PMID:
14625605
20.

Sulphasalazine-induced leucopenia in a patient with renal dysfunction.

Teshima D, Hino B, Makino K, Yano T, Itoh Y, Joh Y, Iida M, Oishi R.

J Clin Pharm Ther. 2003 Jun;28(3):239-42.

PMID:
12795783

Supplemental Content

Loading ...
Support Center